2172 (2172) Fair Value & Analysis

Healthcare · Market cap HK$6.2B

2 2172 2172 · HK

PriceHK$11.00

Fair ValueHK$8.03

Upside-27.0%

Quality60/100

Watch 2172 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$6.02 – HK$10.04

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +17.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$8.62 – HK$15.90 · fair‑value band HK$6.02 – HK$10.04 · the HK$11.00 price screens above the HK$8.03 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2172 (2172) currently trades at HK$11.00, while our model-based Fair Value estimate is HK$8.03 — implying the stock looks roughly 27.0% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2172 generated revenue of HK$790M at a net margin of 23.3%. Revenue grew 15.3% year over year. It earns a return on equity of 10.5%. The balance sheet holds a net cash position of HK$596M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$790M

Revenue growth (YoY) +15.3%

Net margin 23.3%

Return on equity 10.5%

Free cash flow HK$154M FY2025

P/E ratio 29.6

More key figures

Operating margin 39.0%

EPS (TTM) HK$0.1600

Dividend yield 1.1%

EPS growth (YoY) -16.9%

Net cash HK$596M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2172 reported revenue of HK$770M in FY2025 versus HK$383M in FY2021, a compound +19.1%/yr. Reported net income was HK$180M in FY2025, compounding +65.1%/yr from FY2021.

Revenue +19.1%/yr

FY21 HK$383M

FY22 HK$547M

FY23 HK$666M

FY24 HK$762M

FY25 HK$770M

Net income +65.1%/yr

FY21 HK$24.2M

FY22 −HK$21.8M

FY23 HK$146M

FY24 HK$254M

FY25 HK$180M

Is 2172 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,228 MXN	-23%
Abbott Laboratories, ABTT34	R$38.22	R$30.39	-20%
Stryker Corporation S1YK34	R$77.83	R$8.47	-89%
Medtronic plc MDT	$80.25	$74.40	-7%
Boston Scientific Corporation B1SX34	R$248.75	R$221.81	-11%
Edwards Lifesciences Corporation EW	$85.88	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2172 (2172) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$8.03 versus a price of HK$11.00 — about −27% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2172?

Our model-based fair value for 2172 is HK$8.03 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$11.00.

What is the quality score of 2172?

2172 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2172 (2172)?

2172 reported trailing-twelve-month revenue of about HK$790M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2172?

The net profit margin of 2172 is about 23.3%, meaning it keeps roughly 23.3% of revenue as net income. Based on the latest reported figures.

Does 2172 pay a dividend?

2172 currently shows a dividend yield of about 1.13% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.